Clinical Trial Update: A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial of BMS-833923 with carboplatin and etoposide followed by BMS-833923 alone in extensive-stage small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• BMS-833923
• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Small Cell Lung Carcinoma | Phase 1 | Status: COMPLETED